Aethlon Medical, Inc. (NASDAQ:AEMD) Stock Short Interest Falls 83.8%

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 74,846 shares, a drop of 83.8% from the August 31st total of 461,661 shares. Currently, 10.6% of the shares of the company are short sold. Based on an average daily volume of 184,597 shares, the short-interest ratio is presently 0.4 days.

Aethlon Medical Stock Down 7.2%

Shares of AEMD stock opened at $6.28 on Friday. Aethlon Medical has a twelve month low of $1.41 and a twelve month high of $41.35. The company has a market cap of $4.46 million, a P/E ratio of -0.18 and a beta of 1.40. The business has a fifty day simple moving average of $3.10 and a 200 day simple moving average of $7.18.

Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). As a group, equities research analysts anticipate that Aethlon Medical will post -5.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research report on Saturday, August 8th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Aethlon Medical in a report on Friday, September 18th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $1.50.

About Aethlon Medical

Aethlon Medical, Inc is a clinical-stage medical device company focused on developing therapeutic technologies for cancer and life-threatening viral infections. The company’s lead product is the Hemopurifier, an investigational extracorporeal blood filtration device designed to selectively remove certain disease-causing particles, including tumor-derived exosomes and viruses, from the bloodstream.

The Hemopurifier is being evaluated as a potential adjunct to existing treatments. In oncology, the technology is intended to remove exosomes that may contribute to tumor progression and immune suppression.